TriCan Health

You Don't Have to Navigate This Alone

A pancreatic cancer diagnosis changes everything overnight — for patients and for the people who love them. Somewhere in the flood of appointments and decisions, it's easy to feel like you're figuring it all out alone.

But you're not alone. There's a community of patients, caregivers, and advocates who've been exactly where you are — and tools like TriCan built to carry some of the research load for you.

Tag someone who's shown up for you during a hard season.

Learn about TriCan Health → https://www.tricanhealth.com/

Not sure how to start the conversation? Try one of these:

1) “Are there any clinical trials that might be a good fit for my diagnosis?”
2) “Would you be open to me bringing a list of trials I've found for us to discuss?”
3) “If treatment stops working, what trial options would you consider next?”

Your doctor wants you to ask. It's your treatment plan — you're allowed to be an active part of it.

Save this post for your next appointment.

Myth: Clinical trials are only for cancer patients who've run out of options.

Fact: Medical guidelines recommend patients and their doctors consider trials at every stage of treatment. In fact, many pancreatic cancer trials are only for newly diagnosed patients. You're never left without treatment, at any stage.

The best time to explore trial options is as early as possible, to include trial options in your first treatment conversations.

See how trial timing works → https://www.tricanhealth.com/

What Exactly Is a Clinical Trial?

A clinical trial is a research study that tests a new treatment, drug combination, or approach to care, to see if it's safe and more effective than standard treatment options. Clinical trials are how today's standard treatments were discovered, and how tomorrow's better options get found.

If you or someone you love has been diagnosed, trials shouldn't be a last resort. They are an option to consider at every stage of treatment.

Want to see what's out there? TriCan matches your diagnosis to trials that may fit.
Learn more → https://www.tricanhealth.com/

Trican Health takes the stage Friday, August 21st from 3:45–5:30pm CDT at the Seena Magowitz Foundation's Power of Us Conference in Milwaukee.

We'll be busting common clinical trial myths, breaking down how trials actually work, and showing attendees how TriCan's trial finder makes searching simple. If you're there, come say hi!

Not able to join us in Milwaukee? Start your own trial search anytime → tricanhealth.com

This Friday, our team is proud to speak at the Seena Magowitz Pancreatic Cancer Foundation's Power of Us Conference in Milwaukee. It'll be a weekend built for pancreatic cancer patients, survivors, and caregivers, and for learning all about clinical trials!

Our presentation will provide attendees with a practical guide to finding appropriate trials based on diagnosis, prior treatments, and any known biomarkers, enabling everyone to make informed treatment decisions using Trican's patient-friendly trial finder tool.

As 32-year survivor Kay Kays puts it, "Clinical trials should be your appetizer in your treatment, not your dessert." That's the mindset we hope more patients and families embrace, early and often.

Learn more about the conference → seenamagowitzfoundation.org

Come join us in Milwaukee! TriCan Health will be presenting at the Seena Magowitz Pancreatic Cancer Foundation Power of Us conference in Milwaukee, Wisconsin August 21-23, 2026. We'll show survivors how to navigate clinical trials and access promising new medicines currently being evaluated for FDA approval.

Information: https://seenamagowitzfoundation.org/event/power-of-us-2026/

Registration: https://reg.eventmobi.com/power-of-us-2026/register

It's a wonderful opportunity for folks to connect with others who've shared their experience, learn about new treatments on the horizon, and get great information on nutrition and managing side effects.

Register here (e2a0312a-b9b5-40a3-9709-d125ac70363c@a54392ec-492c-4907-95fe-e7eb2191a6e1)" rel="ugc" target="_blank">https://events.teams.microsoft.com/event/e2a0312a-b9b5-40a3-9709-d125ac70363c@a54392ec-492c-4907-95fe-e7eb2191a6e1) for a free webinar Friday June 26th at 11am EDT with Sky Foundation, Inc. and TriCan Health on daraxonrasib, the breakthrough pancreatic cancer medication that got a standing ovation at ASCO.

TriCan Health will be moderating the discussion with two leading physicians/researchers at Karmanos Cancer Institute in Detroit, Dr. Azmi and Dr. Al-Hallak.

Pre-register now and please join us Friday morning for an informative discussion about a 'RAS inhibitor' that doubled the life expectancy of patients in a clinical trial. You can see the research publication here (https://www.nejm.org/doi/full/10.1056/NEJMoa2605555) for more details on the results of the trial.

Great informational video (https://pie.med.utoronto.ca/TVASurg/project/pe-whipple-eng/ ) explaining the pancreas, forms of , and the Whipple surgical procedure, from the Toronto Video Atlas of Surgery - a great resource for patients and surgeons alike.

Helpfully, the video is available in English, French, Spanish and Turkish, as well. The site also has more detailed videos for surgeons on a wide variety of pancreatic surgeries.

Find that include surgery by searching on https://www.tricanhealth.com/ and indicating the tumor is resectable.

TriCan helps cancer patients navigate clinical trials TriCan empowers cancer patients to advocate for their own treatment and gain access to the most advanced medicines available.

Earlier this month, TriCan Health presented at the Pancreas Club meeting in Chicago. It was a great opportunity for pancreas surgeons and others in attendance to get access to a free platform to find best-match clinical trials for patients.

Many thanks to the Nikki Mitchell Foundation for the opportunity!

I had three key takeaways from the meeting:

1. RAS Inhibitors show incredible promise. The physicians in the audience were keenly focused on daraxonrasib and other drugs currently in trials (note - there are 42 (!) different trials in the US targeting RAS recruiting right now)

2. Personalization is king. Companies like Tempus AI provide genomic reports on the mutational burden within each tumor - so not just a binary measure of whether or not a biomarker is present, but to what extent. One pathologist presented research showing that two different tumors from a *single* origin site, metastasized in the *same* organ, might behave differently and therefore might benefit from individualized treatment. So not just personalized medicine per patient - personalized medicine *per tumor*. Amazing.

3. Organoids may help pinpoint effective therapies. An MD PhD at the meeting shared that cells taken from a tumor can be grown to ~1,000-cell organoids within about a week, and then those organoids can be used to select specific therapies, thereby avoiding resistance to typical standard of care adjuvant/neoadjuvant chemotherapies.

Incredible science continues to be conducted to address pancreatic cancer - many thanks to all the researchers and clinicians working every day to improve lives!